Adrenoleukodystrophy (ALD) is a peroxisomal metabolic disorder characterized by the accumulation of very long-chain fatty acids (VLCFAs) in tissues throughout the body, particularly in the white matter of the brain and the adrenal cortex. X-linked adrenoleukodystrophy (X-ALD), caused by mutations in the ABCD1 gene, is the most common form and leads to progressive demyelination of the central nervous system[1].
Oligodendrocytes, the myelin-producing cells of the central nervous system, are particularly vulnerable in ALD due to their high lipid content and dependence on peroxisomal function. VLCFA accumulation in oligodendrocytes disrupts normal myelin synthesis and maintenance, leading to progressive white matter pathology[2].
| Property | Value |
|---|---|
| Category | Glial Cells |
| Location | Cerebral white matter |
| Cell Type | Oligodendrocytes |
| Key Gene | ABCD1 (X-linked ALD) |
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:4042028 | immature neuron |
| Database | ID | Name | Confidence |
|---|---|---|---|
| Cell Ontology | CL:4042028 | immature neuron | Medium |
The ABCD1 gene encodes the peroxisomal ABC transporter ALD protein (ALDP), which is responsible for importing VLCFAs into peroxisomes for β-oxidation. Mutations in ABCD1 lead to impaired VLCFA catabolism and subsequent accumulation[3].
Metabolic consequences in oligodendrocytes:
| Stage | Pathological Event | Clinical Correlation |
|---|---|---|
| Stage 1 | VLCFA accumulation in oligodendrocytes | Asymptomatic |
| Stage 2 | Myelin instability and dysfunction | Mild neurological symptoms |
| Stage 3 | Oligodendrocyte death and demyelination | Progressive neurological decline |
| Stage 4 | Axonal degeneration | Severe disability |
| Stage 5 | Inflammatory response and gliosis | Rapid progression |
| Form | Age of Onset | Features | Prognosis |
|---|---|---|---|
| Childhood cerebral ALD | 4-10 years | Progressive demyelination, cognitive decline | Poor without intervention |
| Adrenomyelononeuropathy (AMN) | Adulthood | Spinal cord involvement, peripheral neuropathy | Variable |
| Addison-only | Variable | Adrenal insufficiency only | May develop cerebral disease |
Dietary therapy:
Cellular therapy:
The study of Oligodendrocytes In Adrenoleukodystrophy has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Kemp S, et al. ABCD1 mutations and the pathogenesis of X-linked adrenoleukodystrophy. Human Mutation. 2012. ↩︎
Barker JE, et al. Very long-chain fatty acid metabolism in oligodendrocytes. Neurochemical Research. 2015. ↩︎
Moser AB, et al. Human and mouse eosinophilic leukemia models for X-linked adrenoleukodystrophy. Journal of Inherited Metabolic Disease. 2012. ↩︎
Eichler F, et al. Hematopoietic stem cell gene therapy for cerebral X-linked adrenoleukodystrophy. Nature Medicine. 2006. ↩︎
Cartwright MS, et al. Gene therapy for adrenoleukodystrophy. Molecular Therapy. 2022. ↩︎